PAIM
ORMP icon

Punch & Associates Investment Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Punch & Associates Investment Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-800
Closed -$6.84K – 217
2015
Q4 		$6.84K Buy
+800
New +$6.06K ﹤0.01% 229

Other funds holding ORMP

TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
GIM
Greylin Investment Management Orange, Virginia $598M AUM 18.59% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return

Punch & Associates Investment Management's ORMP Position: Q1 2016 in Review

Punch & Associates Investment Management sold out of Oramed Pharmaceuticals (ORMP) in Q1 2016, closing a stake of 800 shares — an estimated $6.84K sold.

Punch & Associates Investment Management first reported a position in ORMP in Q4 2015 and held it in 1 quarter. The position peaked at $6.84K in Q4 2015. 25 funds tracked by Wall St. Rank hold ORMP as of Q1 2016.

  • Punch & Associates Investment Management reported no remaining Oramed Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Punch & Associates Investment Management sold 800 Oramed Pharmaceuticals shares in Q1 2016, an estimated $6.84K.
  • Punch & Associates Investment Management first reported a position in Oramed Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Punch & Associates Investment Management's Oramed Pharmaceuticals position peaked at $6.84K in Q4 2015.
  • 25 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2016.

Based on Punch & Associates Investment Management's 13F filing for Q1 2016, filed 25 Apr 2016.